<DOC>
	<DOCNO>NCT01655875</DOCNO>
	<brief_summary>This study patient 2-21 year old acute leukemia respond well chemotherapy bone marrow transplant . This pilot ( phase 1 ) study AMD3100 ( also call Plerixafor , Mozobil ) . AMD3100 give combination standard pre-transplant conditioning regimen ( total body irradiation , etoposide cyclophosphamide ) . The condition regimen treatment give transplant . This treatment kill leukemia cell well healthy bone marrow immune cell . Researchers want learn AMD3100 affect acute leukemia cell . Blood bone marrow sample study participant collect find AMD3100 make patient ' cell sensitive condition regimen find . The first six patient receive three daily dos ( 240 mcg/kg via IV ) . If appear three dos significantly increase side effect transplant conditioning , investigator give second group six patient five daily dos .</brief_summary>
	<brief_title>AMD3100 Sensitizing Allogeneic Blood Marrow Transplant Chemotherapy Resistant Pediatric Acute Leukemia</brief_title>
	<detailed_description>The first six patient receive three daily dos AMD3100 ( 240 mcg/kg via IV ) . If appear three dos significantly increase side effect transplant conditioning , investigator give second group six patient five daily dos . AMD3100 give combination standard pre-transplant conditioning regimen ( total body irradiation , etoposide cyclophosphamide . ) AMD3100 cause healthy bone marrow cell release bone marrow blood collect patient peripheral ( blood stream ) blood stem cell transplant . AMD3100 also push leukemia cell bone marrow . Research animals test tube show bone marrow partially protect leukemia cell chemotherapy radiation . AMD3100 could make leukemia treatment well push leukemia cell bone marrow make sensitive treatment . Clinical trial combine AMD3100 normal dos chemotherapy do relapsed acute leukemia . Researchers hope AMD3100 give condition regimen safely without cause side effect . Up 12 participant enrol estimate accrual duration 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Must chemotherapyresistant acute leukemia ( primary refractory relapse refractory AML , ALL , undifferentiated , bilineage mixed lineage leukemia ) Participant must well HLA match related , mismatch relate unrelated marrow donor patient allele match least 7 8 HLA locus single unrelated cord blood unit match least 4 6 HLA locus minimal dose 4x10 ( 7 ) NC/Kg Prior allogeneic autologous hematopoietic stem cell transplantation Prior exposure AMD3100 Active central nervous system leukemia Uncontrolled viral , bacterial , fungal , protozoal infection HIV infection Does meet standard organ function transplant</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Allogeneic Blood Marrow Transplantation</keyword>
</DOC>